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ABSTRACT
Introduction: Antiplatelet therapy is routinely prescribed early after ischaemic stroke.
Many patients will already be taking antiplatelet therapy and it is unknown whether these
patients should continue the same antiplatelet treatment or switch to a different regimen.
Methods: We selected patients with ischaemic stroke from the Virtual International
Stroke Trials Archive (VISTA) database who were prescribed anti-platelets both
before and after their stroke and who had detailed records of adverse events after stroke.
We compared patients who changed to a new antiplatelet regimen after their stroke to
those who continued the same regimen. The primary outcome was recurrent ischaemic
stroke within 90 days after their index stroke and for secondary outcome was intracerebral
haemorrhage (ICH) or extracranial haemorrhage (ECH). We used logistic regression
analysis and adjusted for age and baseline NIHSS.
Results: A total of 1129 participants were included. Of these, 538 subjects changed
antiplatelet regimen post stroke and 591 continued the same regimen. A recurrent
ischaemic event occurred in 4.1% of subjects who changed regimen and 4.3% who
continued unchanged (adjusted OR=0.93; 95% CI 0.54-1.75, p=0.929). The incidence of
ICH and ECH within the first 90 days was similar in both groups (2.4% vs. 2.6% (adjusted
OR=1.02; 95% CI 0.48-2.18, p=0.955) and 4.7% vs. 2.9% (adjusted OR=1.82; 95% CI
0.96-3.43, p=0.065) respectively).
Conclusion: In patients who suffer ischaemic stroke whilst taking antiplatelets, a change
in antiplatelet regimen was not associated with an altered risk of early recurrent ischaemic
stroke rate or bleeding. However, the results must be interpreted in view of the low event
rates.
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Introduction
Antiplatelet therapy is recommended for patients with ischaemic stroke or transient
ischaemic attack (TIA) due to atherosclerotic disease.1 Antiplatelet drugs are prescribed
to prevent further ischaemic stroke, minimize the risk of early death and to improve long-
term outcome.2, 3
Guidelines recommend that antiplatelet regimens choices are individualised based on
numerous factors including patient risk factor profiles, cost, tolerability and relative
effectiveness.4 One potentially important factor is pre-existing anti-platelet therapy. In
the recently published CHANCE study, at least 20% of patients had history of previous
stroke and 11% of patients had their index stroke whilst taking antiplatelet therapy.5
Guidelines acknowledge that in patients who experience a stroke whilst taking antiplatelet
therapy, there are no clinical trials to show whether switching antiplatelet agents
decreases the risk of subsequent events.6 There are reasons why switching regimen may
be advantageous. Failure of antiplatelet treatment could be due to disease severity (no
drug will be 100% effective), lack of adherence or resistance to effect of the antiplatelet
drug. Resistance to clopidogrel and aspirin exists and studies have shown that aspirin
resistance is associated with an increased risk of cardiovascular events.7 It is possible
resistant patients should be switched to another class of antiplatelet.
In the absence of clinical trial data, we sought to assess whether switching
antiplatelet regimens associated with better outcome than continuing the same
therapy in patients already taking anti-platelet therapy at the time of acute
ischaemic stroke. We hypothesized that a change of antiplatelet regimen would
reduce cardiovascular event rate without increasing bleeding.
Methods
We used data contained in the Virtual International Stroke Trials Archive (VISTA)
database where have been described previously.8 VISTA data are stored at the
Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK. It provides
access to anonymised data collated from completed and monitored clinical trials.
Within VISTA, demographic data such as age, sex and ethnicity; smoking history
and comorbidities as well as details on the index stroke, and functional outcome
measures are contained. Information on adverse events (AE), serious adverse events
(SAE), laboratory measurements and prescribed medications are also available
from certain trials. All clinical trials within VISTA already have local institutional
review board approved procedures in accordance with the Declaration of Helsinki.
Access to data was approved by the VISTA steering committee.
We included patients who had suffered ischaemic stroke whilst taking antiplatelet
drugs (for at least 7 days prior) and who were recommenced on antiplatelet therapy
within 90 days after ischaemic stroke where data on baseline characteristics, medical
history, baseline National Institutes of Health Stroke Scale (NIHSS), occurrence of
adverse and serious adverse events, and medication use with start dates were
recorded in VISTA. We extracted data for these patients.
Data on antiplatelet treatments were based on platelet aggregation inhibitors (which
includes derivatives of salicylic acid, thienopyridine and dipyridamole). Participants were
grouped according to whether they changed antiplatelet regimen (change group) or
continued on the same antiplatelet therapy (continue group).
Our primary outcome was the occurrence of recurrent ischaemic stroke and the
secondary outcome was bleeding complications within 90 days post-stroke. The
modified Rankin Scale (mRS) at 90 days was used to measure the functional
outcomes. We extracted information about recurrent ischaemic stroke and bleeding
complications in all patients from AE and SAE reports. We defined a recurrent
ischaemic stroke as a clear statement of a new adverse event including terms
ischaemic stroke, cerebral infarction or cerebrovascular accident. We did not
include events such as worsening of initial stroke symptoms or oedema. For bleeding
complication, the event was identifies using these key terms: hematoma,
haemorrhage, bleeding, blood or melaena. Bleeding complications were categorized
into two i.e. intracerebral haemorrhage (ICH) and extracranial haemorrhage
(ECH). Intracerebral haemorrhage was defined as any ICH but excluding
haemorrhagic transformation infarction 1 and 2, whereas, ECH was defined as any
bleeding episode from another source.
Statistical analysis
We compared baseline variables in the change and continue groups. Categorical variables
were summarised using frequencies and proportions and were compared using the Chi-
square test or Fisher’s exact test, where appropriate. Continuous variables were
summarised using mean [standard deviation (SD)] or median [interquartile range (IQR)]
and were compared using Student t-test or non-parametric Mann-Whitney test.
We calculated adjusted odds ratios (OR) and corresponding 95% confidence intervals
(95% CI) using binary logistic regression for occurrence of outcomes and ordinal shift of
the mRS at day 90 using the full scale for functional outcomes. Adjustment were made
for age and baseline NIHSS.9, 10 We also assessed the effect of changed or continued
antiplatelet regimen on outcome measures in subgroups: clinical condition (atrial
fibrillation or not, prior stroke or not and treated with intravenous thrombolysis or not).
We conducted subgroup analyses in these populations as their stroke risk recurrence 11, 12
and neurological recovery 13 are different. A p-value <0.05 was used to define statistical
significance. All analyses were performed using IBM SPSS Version 21.0.14
Results
A total of 1129 stroke patients met our inclusion criteria (Figure 1). Forty-eight percent
were changed to a new antiplatelet drug post-stroke. Patient characteristics as shown in
Table 1.
There was no difference in recurrent ischaemic stroke rate between the change and
continue groups (adjusted OR=0.97, 95% CI, 0.54-1.75; p=0.929) (Table 2). The rate of
ICH and ECH was similar in both groups (2.4% vs. 2.6% [adjusted OR=1.02; 95% CI
0.48-2.18, p=0.955] and 4.7% vs. 2.9% [adjusted OR=1.82; 95% CI 0.96-3.43, p=0.065])
respectively. Results were similar regardless of baseline factors such as atrial fibrillation,
history of prior stroke and thrombolysed patients (Figure 2).
The distribution of mRS at 90 days for change versus continue group is shown in Figure
3. We found that change to a new antiplatelet post-stroke was associated with more
favourable functional outcome across a full scale mRS at 90 days after adjustments for
age and baseline NIHSS (adjusted OR, 1.48; 95% CI, 1.19-1.86; p=0.0006), compared
with continue group.

[insert Figure 1]
Figure 1. Flow diagram describing the selection of data from the VISTA for the
analysis reported.
Table 1. Baseline characteristics
Characteristics Change(n=538)
Continue
(n=591) p-value
Age, years* 70.91 (11.25) 72.08 (10.49) 0.091
Male 332 (61.7) 329 (55.7) 0.040
Caucasian 469/527 (89.0) 531/571 (93.0) 0.020
Current Smoker 172/524 (32.8) 145/471 (30.8) 0.491
Baseline NIHSS† 13 (9-17) 14 (9-18) 0.036
Medical history
Hypertension 444/537 (82.7) 448/590 (75.9) 0.005
Diabetes 153/538 (28.4) 155/590 (26.3) 0.414
AF 79/537 (14.7) 135/590 (22.9) <0.001
Heart failure 48/513 (9.4) 51/548 (9.3) 0.978
IHD 229/525 (43.6) 204/471 (43.3) 0.922
Prior TIA 68/490 (13.9) 67/554 (12.1) 0.391
Prior stroke 190/527 (36.1) 133/568 (23.4) <0.001
Thrombolysed, rt-PA 234 (43.5) 174 (29.4) <0.001
AP duration post-stroke
≤ 30 days 109 (20.3) 156 (26.4) 0.041 
31- 60 days 36 (6.7) 31 (5.2)
61- 90 days 393 (73.0) 404 (68.4)
All values are reported as no. (%) unless otherwise noted. *Values are reported
as mean (SD); †median (IQR). AF=atrial fibrillation, AP=antiplatelet, IHD=
ischaemic heart disease, NIHSS=National Institutes of Health Stroke Scale, rt-
PA=recombinant tissue plasminogen activator. TIA=transient ischaemic attack,
SD=standard deviation, IQR=interquartile range.
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Table 2. Clinical outcomes at 90 days (adjusted for age and baseline NIHSS).
Outcomes Changen=538
Continue
n=591
Adjusted OR
(95% CI) p-value
Recurrent
ischaemic stroke
22/532
(4.1)
25/588
(4.3) 0.97 (0.54-1.75) 0.929
ICH 13/532(2.4)
15/581
(2.6) 1.02 (0.48-2.18) 0.955
ECH 25/527(4.7)
17/584
(2.9) 1.82 (0.96-3.43) 0.065
All values are reported as no. (%) unless otherwise noted. CI=confidence interval,
ICH=intracranial haemorrhage, ECH=extracranial haemorrhage, OR=odds ratio.
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[insert Figure 2]
Figure 2. Clinical outcomes at 90 days (adjusted for age and baseline NIHSS) by
subgroup. All values are reported as no. (%) unless otherwise noted. AF=atrial
fibrillation, OR=odds ratio, CI=confidence interval.
[insert Figure 3]
Figure 3. Distribution of mRS outcome at day 90 in patients suffering ischaemic
stroke. Diagram showing association of functional outcome at day 90 between
change and continue group. Values provided in each box denote the percentage of
patients belonging to a specific treatment category (change or continue) and
representing the mRS score corresponding to the box.
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Discussion
In the present study we found that subjects who experience stroke while on antiplatelet therapy
and who switch to a new class of antiplatelet regimen after stroke do not have a lower early
recurrence rate than subjects who continue with the same antiplatelet therapy. We also found
no difference in bleeding outcomes. Furthermore, the clinical outcomes were not significantly
different across pre-defined subgroups. We found that change group was associated with an
increase in the odds of a favourable functional outcome.
Many patients suffer ischaemic stroke despite taking antiplatelet therapy. Some studies
show that, in ischaemic heart disease, patients who are non-responders to aspirin and
clopidogrel are at greater risk of subsequent ischaemic vascular event and death.15 It is
therefore attractive to suggest that changing antiplatelet class will be of benefit, and
reduce subsequent recurrence, in patients who are admitted with ischaemic stroke despite
antiplatelets. This would be a cheap, immediately available way of reducing risk. Another
study found the rate of adverse clinical outcomes was significantly higher in antiplatelet-
regimen-modified group than those without modification.16
There are no trials that show changed antiplatelet therapy after a stroke event reducing the risk
of subsequent stroke.4 A recent retrospective cohort study by Lee et al.17 compared clopidogrel
initiation versus aspirin re-initiation among patients with ischaemic stroke who took aspirin at
least 30 days prior to their index of stroke. They found those who changed to clopidogrel after
a stroke was associated with fewer vascular events than aspirin. In contrast, we did not find
any significant relation between those who change and continue antiplatelet therapy. The
reasons might be because our study follow-up was shorter i.e. 90 days compared to study by
Lee et al.17 and other related trials which are normally more than 2 years.18 Furthermore, we
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divided patients into two different groups, whether they change or continue with the same
antiplatelet therapy and not according to specific antiplatelet agent.
We found those who changed antiplatelet regimen had better functional outcome at 90
days than those in continue group. Although we tried to adjust for differences in baseline
factors, this most likely reflects residual confounding and may reflect regional differences
in stroke care. A physician may choose a more aggressive (or change) approach in
patients with better prognosis. Such differences may affect functional outcomes but not
recurrence risk. In our study the change group had lower stroke severity and fewer
patients with atrial fibrillation at baseline, both factors are known to associate with an
increased risk of poor outcome following an ischaemic stroke.19-23
There are several limitations to this study. The analysis was performed using a non-randomized
registry data that derived from various clinical trials. Thus, selection and other biases could
have confounded antiplatelet therapy choices. The number of included participants was low
due to the selection criteria, the need to be on antiplatelet therapy before and after stroke and
the need for the start dates of prior and new medications to be recorded. Although the recurrent
ischaemic stroke rate was identical between groups, we lack statistical power to exclude a
potentially clinically significant difference between groups. We unable to investigate stroke
recurrence based on stroke subtype as the information are not available in most of the patients.
We lack specific measures of medication compliance, particularly before the stroke,
which could be a cause of failure of treatment. The effects of switching drugs class in such
patients may be different and this will need to be addressed by further study. We also
lack information on discharge time, which could be related to compliance and to
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functional outcomes. We did not have information on all variables to calculate
CHAD2VASC score and only 19% of our patients had AF.
There are also strengths to our study. The data are derived from prospective trials with
standardized assessments and careful data monitoring, providing high quality data. In addition,
we were able to adjust for the most important prognostic variables.
In summary, we found no difference in outcomes in patients who continued the same
antiplatelets after stroke or who changed. Despite no clear evidence for changing antiplatelet
strategies following a cardiovascular event, over 50% of patients had their medication changed.
This may reflect uncertainty or the fact guidelines. As recommended by the guideline, the
selection of antiplatelet regimen after ischaemic stroke however, should be individualized on
the basis of patient risk factor profiles, cost, tolerance and other clinical characteristics.4
However, this was a small retrospective analysis and future prospective trials will be needed.
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